# Peptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-mutant

> **NCT05457959** · PHASE1 · WITHDRAWN · sponsor: **Jonsson Comprehensive Cancer Center**

## Conditions studied

- Diffuse Hemispheric Glioma, H3 G34-Mutant

## Interventions

- **BIOLOGICAL:** Dendritic Cell Tumor Peptide Vaccine
- **BIOLOGICAL:** Ipilimumab
- **PROCEDURE:** Leukapheresis
- **BIOLOGICAL:** Nivolumab
- **DRUG:** Placebo Administration
- **DRUG:** Placebo Administration
- **DRUG:** Poly ICLC
- **PROCEDURE:** Resection

## Key facts

- **NCT ID:** NCT05457959
- **Lead sponsor:** Jonsson Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-12-01
- **Primary completion:** 2029-12-01
- **Final completion:** 2030-12-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Never opened
- **Last updated:** 2025-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05457959

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05457959, "Peptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-mutant". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05457959. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*